Business

Akero rises on planned release of mid-stage data on liver disease asset

Posted by

[ad_1]

Hepatitis virus with human liver

Rasi Bhadramani

  • Akero Therapeutics (NASDAQ:AKRO) is up ~5% in after-hours trading Friday after announcing it will hold a conference call Jan. 27 to discuss topline results from a phase 2b study of efruxifermin in patients with compensated cirrhosis due to metabolic

[ad_2]

Leave a Reply

Your email address will not be published. Required fields are marked *